Five of our most advanced and high-potential clinical and preclinical assets are being progressed to their next inflection points.
- Target
- Chemistry and Lead Optimisation
- Preclinical
- Phase I
- Phase II
Regular re-evaluation of 10+ BenevolentAI paused programmes and potential new pipeline entries:
- demonstrates utility to find novel insights previously not connect in the literature; and
- develop and advance unique and differentiated molecules.